

# Tuberculosis profile: Thailand

Population 2022: 72 million

## Estimates of TB burden\*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	111 000 (87 000-138 000)	155 (122-193)
HIV-positive TB incidence	9 200 (6 200-13 000)	13 (8.6-18)
MDR/RR-TB incidence**	2 700 (1 500-3 800)	3.7 (2.1-5.3)
HIV-negative TB mortality	12 000 (9 500-14 000)	16 (13-20)
HIV-positive TB mortality	2 100 (1 400-2 800)	2.9 (2-4)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2022

New cases	1.7% (1.1-2.5)
Previously treated cases	9.7% (9.1-10)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2022	65% (52-83)
TB patients facing catastrophic total costs, 2020	30% (26-34)
TB case fatality ratio (estimated mortality/estimated incidence), 2022	12% (9-16)

## TB case notifications, 2022

Total new and relapse	72 274
- % tested with rapid diagnostics at time of diagnosis	60%
- % with known HIV status	84%
- % pulmonary	86%
- % bacteriologically confirmed ^	73%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	31%
- % men (aged ≥15 years)	68%
Total cases notified	73 584

## TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	5 340	8.8%
- on antiretroviral therapy	4 689	88%

## Drug-resistant TB care\*\*, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	75%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	81%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	875
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	874
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	50
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	48
MDR/RR-TB cases tested for resistance to any fluoroquinolone	384

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	85%	71 488
Previously treated cases, excluding relapse, registered in 2021	62%	569
HIV-positive TB cases registered in 2021	72%	5 313
MDR/RR-TB cases started on second-line treatment in 2020	72%	1 142
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	73%	62


## TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	15% (14-15)


## Funding for TB

Funding for TB, 2022 (US\$ millions)	26
- % domestic funding	77%
- % international funding	23%
National TB budget, 2023 (US\$ millions)	29
- Funding source, domestic	78%
- Funding source, international	22%
- Unfunded	0%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




## HIV-negative TB mortality (Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2022 (Number)



## Cases attributable to five risk factors, 2022 (Number)



## Funding for TB (US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.  
\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone  
^ Calculated for pulmonary cases only  
^^ Includes cases with unknown previous TB treatment history  
^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed

---

Generated 2023-12-16 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)